Description: Ibalizumab(TMB-355) is a humanized IgG4 monoclonal antibody that acts as a CD4 receptor inhibitor, blocking the entry of HIV-1 into cells by binding to the CD4 receptor.Ibalizumab has anti-HIV-1 infectious activity and may be used to maintain normal immune function.
CAS Number: 680188-33-4
References: Anthony Markham. Ibalizumab: First Global Approval. Drugs. 2018 May;78(7):781-785.